ArticleFrontiers in immunology2025

A 20-year real-world study on drug survival and predictive factors for infliximab discontinuation in Behçet's syndrome.

Rosaria Talarico et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.